Abstract:  Chronic kidney disease-mineral and bone  disorder  （CKD-MBD） refers  to  a  syndrome  of  mineral  and bone metabolism abnormalities caused by chronic kidney disease.  It can affect the  cardiovascular  system and bone  tissue， eventually leading to damage to multiple organs  and systems  throughout  the  body， making  it  a  significant  cause  of  patient mortality. Hyperphosphatemia is the initiating factor of CKD-MBD， making the  management  of  blood phosphorus  levels  in dialysis patients extremely important; however， the rate of achieving target blood phosphorus levels in these patients is not high. In recent years， a series of new phosphate-lowering drugs have been developed based on new mechanisms， including iron-based  phosphate   binders，   calcium-magnesium   composite   phosphate   binders，   and   niacinamide，   among   others. Additionally， there  are  some  novel  phosphate-lowering  drugs  undergoing  clinical  trials.  This  article  reviews  the  current status of  blood  phosphorus  management  in  dialysis  patients  and  the  effects  and  characteristics  of  these  new  phosphate- lowering drugs.

Key words: chronic , kidney , disease-mineral , and , bone , disorder ,  ,  hyperphosphatemia ,  ,  , hemodialysis ,  , phosphate- lowering drugs